BioStock: Alzinova comments on the FDA Fast Track Designation

Alzinova continues to advance the development of its therapeutic vaccine ALZ-101 for Alzheimer’s disease. The FDA has granted the candidate Fast Track designation – an important regulatory milestone that could help accelerate development and review. With both IND clearance for the upcoming phase II study and the Fast Track designation in hand, Alzinova is strengthening its clinical position ahead of the next stage, while also expected to draw increasing interest from potential partners and investors. We reached out to CEO Tord Labuda for a comment.

Read the full article at biostock.se:

https://biostock.se/en/2025/10/alzinova-kommenterar-fast-track-fran-fda/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se